LSLinn Stenfelt

Linn Stenfelt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Linn Stenfelt has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular basis for the efficiency of an Akkermansia muciniphila α-1,2-fucosidase on conjugated H and Lewis epitopes

    by Mathias Jensen, Marina Corbella, Linn Stenfelt, Martin L. Olsson, Jens Preben Morth, Carme Rovira, Maher Abou Hachem

  • Open Access

    Molecular Basis for the Efficiency of an Akkermansia muciniphila α-1,2-Fucosidase on Conjugated H and Lewis Epitopes

    by Mathis Jensen, Marina Corbella Morato, Linn Stenfelt, Martin L. Olsson, Jens Preben Preben Morth, Carme Rovira, Maher Abou Hachem

    H and Lewis (Le) antigens mediate host-microbe interactions and are immune-determinants in the ABO blood system. α-1,2-Fucosidases active on these antigens are of considerable interest for glycoengineering applications, notably within transfusion medicine. How α-1,2-fucosidases recognize H and Le antigens remains hitherto unexplored. Here, we use X-ray crystallography, molecular dynamics simulations and mutagenesis to reveal that multiple H and Le antigens of different composition and conformations are recognized by the same subsites in an α-1,2-fucosidase from the mucin-degrader Akkermansia muciniphila. A secondary fucosyl binding subsite, previously not reported in α-fucosidases, was shown to govern catalytic efficiency towards di-fucosylated H type 3 and Le substrates. Mutational analyses indicated that enzyme-glycan interactions beyond the active site modulate catalytic efficiency on conjugated substrates. Our findings highlight unprecedented structural features that underpin catalytic efficiency towards mucosal or cell surface human glycoconjugates, offering a framework for the design of α-1,2-fucosidase tailored for specific biomedical applications.

  • Akkermansia muciniphila exoglycosidases target extended blood group antigens to generate ABO-universal blood

    by Mathias Jensen, Linn Stenfelt, Jennifer Ricci Hagman, Michael Jakob Pichler, Julia Weikum, Tine Sofie Nielsen, Annika Hult, Jens Preben Morth, Martin L. Olsson, Maher Abou Hachem

    Matching donor and recipient blood groups based on red blood cell (RBC) surface ABO glycans and antibodies in plasma is crucial to avoid potentially fatal reactions during transfusions. Enzymatic conversion of RBC glycans to the universal group O is an attractive solution to simplify blood logistics and prevent ABO-mismatched transfusions. The gut symbiont Akkermansia muciniphila can degrade mucin O-glycans including ABO epitopes. Here we biochemically evaluated 23 Akkermansia glycosyl hydrolases and identified exoglycosidase combinations which efficiently transformed both A and B antigens and four of their carbohydrate extensions. Enzymatic removal of canonical and extended ABO antigens on RBCs significantly improved compatibility with group O plasmas, compared to conversion of A or B antigens alone. Finally, structural analyses of two B-converting enzymes identified a previously unknown putative carbohydrate-binding module. This study demonstrates the potential utility of mucin-degrading gut bacteria as valuable sources of enzymes for production of universal blood for transfusions.


  • Open Access

    Glycoproteomic and Phenotypic Elucidation of B4GALNT2 Expression Variants in the SID Histo-Blood Group System

    by Linn Stenfelt, Jonas Nilsson, Åsa Hellberg, Yew Wah Liew, Jenny Morrison, Göran Larson, Martin L. Olsson

    The Sda histo-blood group antigen (GalNAcβ1-4(NeuAcα2-3)Galβ-R) is implicated in various infections and constitutes a potential biomarker for colon cancer. Sd(a−) individuals (2–4% of Europeans) may produce anti-Sda, which can lead to incompatible blood transfusions, especially if donors with the high-expressing Sd(a++)/Cad phenotype are involved. We previously reported the association of B4GALNT2 mutations with Sd(a−), which established the SID blood-group system. The present study provides causal proof underpinning this correlation. Sd(a−) HEK293 cells were transfected with different B4GALNT2 constructs and evaluated by immunostaining and glycoproteomics. The predominant SIDnull candidate allele with rs7224888:T>C (p.Cys406Arg) abolished Sda synthesis, while this antigen was detectable as N- or O-glycans on glycoproteins following transfection of wildtype B4GALNT2. Surprisingly, two rare missense variants, rs148441237:A>G and rs61743617:C>T, found in a Sd(a−) compound heterozygote, gave results similar to wildtype. To elucidate on whether Sd(a++)/Cad also depends on B4GALNT2 alterations, this gene was sequenced in five individuals. No Cad-specific changes were identified, but a detailed erythroid Cad glycoprotein profile was obtained, especially for glycophorin-A (GLPA) O-glycosylation, equilibrative nucleoside transporter 1 (S29A1) O-glycosylation, and band 3 anion transport protein (B3AT) N-glycosylation. In conclusion, the p.Cys406Arg β4GalNAc-T2 variant causes Sda-deficiency in humans, while the enigmatic Cad phenotype remains unresolved, albeit further characterized.


  • Open Access

    Missense mutations in the C-terminal portion of the B4GALNT2-encoded glycosyltransferase underlying the Sd(a−) phenotype

    by Linn Stenfelt, Åsa Hellberg, Mattias Möller, Nicole Thornton, Göran Larson, Martin L. Olsson


  • The P1 histo‐blood group antigen is present on human red blood cell glycoproteins

    by Linn Stenfelt, Julia S. Westman, Åsa Hellberg, Martin L. Olsson

    BACKGROUND: The P1 antigen was first described in 1927 and belongs to the P1PK histo‐blood group system, together with Pk and NOR. The A4GALT‐encoded 4‐α‐galactosyltransferase synthesizes these antigens and has been considered to extend glycolipids exclusively. However, contradicting studies have been published regarding the presence of P1 on human glycoproteins. In other species, P1 occurs on glycoproteins. Furthermore, human ABH antigens occur on both glycolipids and glycoproteins and are biochemically related to P1. Thus, we hypothesized that P1 is present on RBC glycoproteins in humans.STUDY DESIGN AND METHODS: RBCs of known P1/P2 status (phenotype and rs8138197 genotype) were used. The RBC surface glycans were modified with α‐galactosidases, papain, and/or peptide‐N‐glycosidase F. RBC membrane proteins were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis/immunoblot. A new P 1/P 2‐allelic discrimination assay based on rs5751348 was validated.RESULTS: P1 occurs on various glycoproteins, seen as smearlike patterns in anti‐P1‐stained immunoblots with RBC membranes of P1 but not P2 or p phenotype. There was a significant difference between the staining of P 1‐homozygous and P 1‐heterozygous RBCs (P 1P 1 > P 1P 2), as well as intragenotypic variation. Immunoblotting banding patterns show major carriers at approximately 50 and 100 kDa. P1 staining was lost after treatment of RBCs with α‐galactosidase of broad Galα‐1,3/4/6‐specificity. Peptide‐N‐glycosidase F treatment reduced the P1 signal, while papain or α‐1,3‐specific galactosidase did not. P 1/P 2 status was confirmed by a new rs5751348 assay.CONCLUSION: Our data indicate that the P1 antigen can reside on human RBC glycoproteins. Glycosidase studies suggest that at least part of the epitopes occur on N‐glycans.


  • Allele-selective RUNX1 binding regulates P1 blood group status by transcriptional control of A4GALT

    by Julia S. Westman, Linn Stenfelt, Karina Vidovic, Mattias Möller, Åsa Hellberg, Sven Kjellström, Martin L. Olsson

    P1 and Pk are glycosphingolipid antigens synthesized by the A4GALT-encoded α1,4-galactosyltransferase, using paragloboside and lactosylceramide as acceptor substrates, respectively. In addition to the compatibility aspects of these histo-blood group molecules, both constitute receptors for multiple microbes and toxins. Presence or absence of P1 antigen on erythrocytes determines the common P1 (P1+Pk+) and P2 (P1-Pk+weak) phenotypes. A4GALT transcript levels are higher in P1 individuals and SNPs in non-coding regions of A4GALT, particularly rs5751348, correlate with P1/P2 status. Despite these recent findings, the molecular mechanism underlying these phenotypes remains elusive. The In(Lu) phenotype is caused by KLF1 haploinsufficiency and shows decreased P1 levels on erythrocytes. We therefore hypothesized KLF1 to regulate A4GALT expression. Intriguingly, P1-specific sequences including rs5751348 revealed potential binding sites for several hematopoietic transcription factors, including KLF1. However, KLF1 binding did not explain P1-specific EMSA shifts and siRNA silencing of KLF1 did not affect A4GALT transcript levels. Instead, protein pull-down experiments using P1 but not P2 oligonucleotide probes identified RUNX1 by mass spectrometry. Furthermore, RUNX1 binds P1 alleles selectively and knockdown of RUNX1 significantly decreased A4GALT transcription. These data indicate that RUNX1 regulates A4GALT and thereby the expression of clinically important glycosphingolipids implicated in blood-group incompatibility and host-pathogen interactions. Key points The intronic A4GALT SNP rs5751348 defines a hematopoietic transcription factor-binding site present in P1 but not P2 blood group alleles. RUNX1 selectively binds to this regulatory site in P1 alleles, and siRNA knock-down of RUNX1 downregulates A4GALT transcript levels.